Speakers:
Organizers: Kevin Grimes (Stanford), Shichang Miao (ChemoCentryx), Snow Ge (Nektar), Greg Wagner
Date: 2019-03-07
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $50; Students/Postdocs & Unemployed: $20
Location: Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date: (9)Applied StemCell; Averica Discovery Services; MagArray; Medpace; Novogene Corporation; Pacific BioLabs; PeproTech Inc; PHC former Panasonic Healthcare; R&D Systems
Registration: http://www.PBSS.org
Registration deadline:2019-03-05  (it will close sooner if the seating cap is reached)

About the Topic

This joint symposium between PBSS and the Stanford SPARK translational research program will review how industry and academia can work together to successfully translate academic research into commercial opportunities and will present examples of current and past SPARK projects. 

Academics often make promising discoveries that could lead to novel therapeutics, but lack the expertise to advance their science to a stage here commercial partners would be interested. The Stanford SPARK program is a collaboration between academic scientists and individuals from the local biopharmaceutical community who are willing to share their knowledge and expertise. SPARK is now in its twelfth year and nearly 50% of projects completing the program have been transferred to commercial partners. An additional 10% have entered investigator-initiated clinical trials. 

Agenda: 

8:45- 8:55           Welcome Remarks (Shichang Miao, Kevin Grimes)

8:55- 9:30           Introduction to the Stanford SPARK Translational Research Program and Overview of Drug Discovery in the Academic Setting (Kevin Grimes, Professor, Co-Director of SPARK, Stanford)

9:30- 10:05         Peptide therapeutics for heart failure (or for Huntington's disease) (Daria Mochly-Rosen, Professor, Co-Director of SPARK, Stanford)

10:05-10:40        myc animal models and two therapeutic projects (Dean Felsher, Professor, Stanford)

10:40- 11:00       Break

11:00- 11:35       New treatment for dementia (Mehrdad Shamloo, Professor, Stanford)

11:35- 12:10       Antivirals targeting the host  (Shirit Einav, Professor, Stanford)

12:10- 1:00         Lunch

1:00- 1:35           Genomically-modfied cell therapies for IPEX syndrome (Rosa Bacchetta, Professor, Stanford)

1:35- 2:10           Drug target overview and selection: from the industry perspective (Nancy Pryer, Chief Development Officer, Nurix)

2:10- 2:45           Clinical candidate selection (John Link, VP  Medchem, Gilead)

2:45- 3:00           Break

3:00- 3:35           Funding for startups: seed/angel/VC funding and non-dilutive funding such as SBIR (Keith Wycoff, VP Research, Planet Biotechnology)

3:35- 4:10           GMP overview for small and/or large molecules (Kenneth Matthews, Gilead)

4:10- 4:45           IP considerations when starting a company: Avoid the Pitfalls and Set for Success (Janet Xiao, Partner, Morrison Foerster)

4:45- 5:15           Panel Discussion